Article

High-Cost Blood Cancer Drugs Deliver High Value

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent.

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent.

Researchers present this viewpoint, based upon a comprehensive analysis of published cost-effectiveness ratios, online today in Blood, the Journal of the American Society of Hematology. The manuscript is being published as a Blood Forum article, a feature of the journal designed to present well-documented opinions on controversial topics and provide a sounding board for issues of importance to the science and practice of hematology.

Read the press release from the American Society of Hematology: http://bit.ly/1CCdkzH

Related Videos
Dr Mingyang Song
Dr Samantha Garcia
John Michael O'Brien, PharmD, MPH
Dr Duke Appiah
5 experts are featured in this series
4 experts are featured in this series.
5 experts are featured in this series
4 experts are featured in this series.
Lalan Wilfong, MD
Katherine Baker, MD, MMHC
Related Content
COA logo | Image Credit: © Amy Kinnamon
May 2nd 2025

Community Oncology Reacts to Trump's Drug Pricing Executive Order

Maggie L. Shaw
An executive order signed on Tuesday, May 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
managed care cast logo
April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD
On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Andrew Evens, DO
May 2nd 2025

Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO

Kyle Munz Andrew Evens, DO
To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
In the Press
May 2nd 2025

AJMC® in the Press, May 2, 2025

Julia Bonavitacola
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Asthma and Allergy Awareness. | Image Credit: Neelrong - stock.adobe.com
May 2nd 2025

National Asthma and Allergy Awareness Month: Economic Costs, Threats to Access, and the Impact of Policy Changes

Cameron Santoro
During National Asthma and Allergy Awareness Month, the high prevalence and costs of allergies and asthma in the US are evident, alongside disparities in treatment access and the potential impact of recent policy changes on environmental and public health efforts.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo